AR106384A1 - Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-il]-nicotinonitrilo como inhibidores irak - Google Patents
Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-il]-nicotinonitrilo como inhibidores irakInfo
- Publication number
- AR106384A1 AR106384A1 ARP160103166A ARP160103166A AR106384A1 AR 106384 A1 AR106384 A1 AR 106384A1 AR P160103166 A ARP160103166 A AR P160103166A AR P160103166 A ARP160103166 A AR P160103166A AR 106384 A1 AR106384 A1 AR 106384A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- optionally substituted
- independently
- solvate
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000000589 Interleukin-1 Human genes 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- -1 P (= O) (OH) 2 Chemical group 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud describe compuestos que inhiben las quinasas de la familia IRAK (interleuquina 1), métodos para su producción, composiciones farmacéuticas que comprenden los mismos, y métodos de tratamiento que utilizan los mismos, para la profilaxis y/o tratamiento de enfermedades inflamatorias, enfermedades autoinmunes y/o enfermedades proliferativas mediante la administración del compuesto de la presente. Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), en donde Cy es cicloalquilo C₃₋₇ monocíclico opcionalmente sustituido con uno o más R³ seleccionado independientemente, o heterocicloalquilo monocíclico de 4 - 7 miembros que comprende uno o dos heteroátomos seleccionados independientemente de N, S, y O, opcionalmente sustituido con uno o más R³ seleccionado independientemente; R¹ es H, SO₃H, P(=O)(OH)₂, alquilo C₁₋₄, C₍₌O₎₋₍ₕₑₜₑʳₒᶜⁱᶜₗₒₐₗqᵘⁱₗₒ ₘₒₙₒᶜíᶜₗⁱᶜₒ ᵈₑ ₄ ₋ ₇ ₘⁱₑₘᵇʳₒₛ qᵘₑ ᶜₒₘₚʳₑₙᵈₑ ᵘₙₒ ₒ ᵈₒₛ ₕₑₜₑʳₒáₜₒₘₒₛ ₛₑₗₑᶜᶜⁱₒₙₐᵈₒₛ ⁱₙᵈₑₚₑₙᵈⁱₑₙₜₑₘₑₙₜₑ ᵈₑ N, S ʸ O₎, ₒ C₍₌O₎ₐₗqᵘⁱₗₒ C₁₋₆, alquilo C₁₋₆ que está opcionalmente sustituido con uno o más grupos R⁴ seleccionados independientemente; R² es H o alquilo C₁₋₄; cada R³ se selecciona independientemente de: OH, =O, halo, y alquilo C₁₋₄; cada R⁴ se selecciona independientemente de: NR⁵ᵃR⁵ᵇ, C(=O)OH, heterocicloalquilo monocíclico de 4 - 7 miembros que comprende uno o dos heteroátomos seleccionados independientemente de N, S, y O, opcionalmente sustituido con uno o más alquilo C₁₋₄ seleccionados independientemente, y NHC(=O)-alquilo C₁₋₄-NH₂; y R⁵ᵃ y R⁵ᵇ son independientemente H o alquilo C₁₋₄; o una sal farmacéuticamente aceptable o un solvato o la sal de un solvato del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1518456.7A GB201518456D0 (en) | 2015-10-19 | 2015-10-19 | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106384A1 true AR106384A1 (es) | 2018-01-10 |
Family
ID=55131239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103166A AR106384A1 (es) | 2015-10-19 | 2016-10-17 | Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-il]-nicotinonitrilo como inhibidores irak |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10508111B2 (es) |
| EP (1) | EP3365341B1 (es) |
| JP (1) | JP2018530617A (es) |
| KR (1) | KR20180064528A (es) |
| CN (1) | CN108137584A (es) |
| AR (1) | AR106384A1 (es) |
| AU (1) | AU2016343225A1 (es) |
| BR (1) | BR112018007392A2 (es) |
| CA (1) | CA3002255A1 (es) |
| CO (1) | CO2018004765A2 (es) |
| GB (1) | GB201518456D0 (es) |
| IL (1) | IL258707A (es) |
| MX (1) | MX2018004517A (es) |
| PH (1) | PH12018500827A1 (es) |
| RU (1) | RU2018117499A (es) |
| SG (1) | SG11201803095UA (es) |
| TW (1) | TW201718582A (es) |
| WO (1) | WO2017067848A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| GB201702603D0 (en) * | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| GB201904373D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY28506A1 (es) * | 2003-09-12 | 2005-04-29 | Basf Ag | 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales. |
| ES2389203T3 (es) * | 2004-01-12 | 2012-10-24 | Ym Biosciences Australia Pty Ltd | Inhibidores de quinasa selectivos |
| CN103476767B (zh) * | 2011-02-09 | 2015-06-10 | 弗·哈夫曼-拉罗切有限公司 | 作为pi3激酶抑制剂的杂环化合物 |
| BR112016006319A2 (pt) * | 2013-09-27 | 2017-08-01 | Nimbus Iris Inc | inibidores de irak e usos dos mesmos |
| UY35935A (es) * | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
-
2015
- 2015-10-19 GB GBGB1518456.7A patent/GB201518456D0/en not_active Ceased
-
2016
- 2016-10-14 CA CA3002255A patent/CA3002255A1/en not_active Abandoned
- 2016-10-14 BR BR112018007392A patent/BR112018007392A2/pt not_active Application Discontinuation
- 2016-10-14 EP EP16794525.2A patent/EP3365341B1/en active Active
- 2016-10-14 MX MX2018004517A patent/MX2018004517A/es unknown
- 2016-10-14 CN CN201680060910.6A patent/CN108137584A/zh active Pending
- 2016-10-14 RU RU2018117499A patent/RU2018117499A/ru not_active Application Discontinuation
- 2016-10-14 WO PCT/EP2016/074662 patent/WO2017067848A1/en not_active Ceased
- 2016-10-14 AU AU2016343225A patent/AU2016343225A1/en not_active Abandoned
- 2016-10-14 US US15/769,260 patent/US10508111B2/en not_active Expired - Fee Related
- 2016-10-14 KR KR1020187013738A patent/KR20180064528A/ko not_active Withdrawn
- 2016-10-14 SG SG11201803095UA patent/SG11201803095UA/en unknown
- 2016-10-14 JP JP2018538935A patent/JP2018530617A/ja not_active Ceased
- 2016-10-17 AR ARP160103166A patent/AR106384A1/es unknown
- 2016-10-18 TW TW105133608A patent/TW201718582A/zh unknown
-
2018
- 2018-04-15 IL IL258707A patent/IL258707A/en unknown
- 2018-04-17 PH PH12018500827A patent/PH12018500827A1/en unknown
- 2018-05-03 CO CONC2018/0004765A patent/CO2018004765A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018007392A2 (pt) | 2018-10-16 |
| US10508111B2 (en) | 2019-12-17 |
| TW201718582A (zh) | 2017-06-01 |
| MX2018004517A (es) | 2018-06-27 |
| RU2018117499A (ru) | 2019-11-21 |
| SG11201803095UA (en) | 2018-05-30 |
| WO2017067848A1 (en) | 2017-04-27 |
| EP3365341B1 (en) | 2020-05-13 |
| IL258707A (en) | 2018-06-28 |
| US20180305351A1 (en) | 2018-10-25 |
| PH12018500827A1 (en) | 2018-10-29 |
| CA3002255A1 (en) | 2017-04-27 |
| GB201518456D0 (en) | 2015-12-02 |
| CN108137584A (zh) | 2018-06-08 |
| CO2018004765A2 (es) | 2018-07-19 |
| RU2018117499A3 (es) | 2020-01-24 |
| AU2016343225A1 (en) | 2018-05-10 |
| KR20180064528A (ko) | 2018-06-14 |
| JP2018530617A (ja) | 2018-10-18 |
| EP3365341A1 (en) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001744A1 (es) | Derivados de benzoxazol como inmunomoduladores. | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
| CL2021001098A1 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| EA201690094A1 (ru) | Ингибиторы syk | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| EA201592182A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| MX2017004129A (es) | Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2- il)amino-benzoico como inhibidor de quinasa p38. | |
| UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR106384A1 (es) | Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-il]-nicotinonitrilo como inhibidores irak | |
| PE20181778A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue | |
| EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201690129A1 (ru) | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| EA201600636A1 (ru) | 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды | |
| CR20160528A (es) | Compuestos y composiciones para inducir condrogénesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |